临床误诊误治2025，Vol.38Issue(4)：43-49,7.DOI:10.3969/j.issn.1002-3429.2025.04.009
不同剂量奥拉帕利联合贝伐珠单抗治疗老年复发性铂敏感型卵巢癌的效果分析
Effect Analysis of Different Doses of Olaparib Combined with Bevacizumab in the Treatment of Platinum-sensitive Recurrent Ovarian Cancer in the Elderly
摘要
Abstract
Objective To analyze the effects of different doses of Olaparib combined with Bevacizumab on clinical ef-ficacy,serum tumor markers and T lymphocyte subsets in elderly patients with platinum-sensitive recurrent ovarian cancer.Methods A total of 140 elderly patients with platinum-sensitive recurrent ovarian cancer diagnosed from January 2019 to Jan-uary 2021 were randomly divided into high-dose group(n=70)and low-dose group(n=70)by envelope method.The low-dose group was treated with Olaparib(150 mg orally,2/d)combined with Bevacizumab injection,and the high-dose group was treated with Olaparib(300 mg orally,2/d)combined with Bevacizumab injection.The median progression-free survival(PFS),disease control rate(DCR),objective response rate(ORR)and the incidence of adverse drug reactions during treat-ment were observed.Serum tumor markers[human epididymal protein 4(HE4),cancer antigen 125(CA125),cancer anti-gen 199(CA199)],T lymphocyte subsets and quality of life scale scores were compared between the two groups before treat-ment and after 2,4 and 6 cycles of treatment.Results After treatment,there was no significant difference in ORR and DCR between the two groups(P＞0.05).Compared with those before treatment,life quality scale scores and peripheral blood CD3+,CD4+,CD4+/CD8+levels in the two groups after 2,4 and 6 cycles of treatment were gradually increased,while serum HE4,CA125 and CA199 levels were gradually decreased(P＜0.05).After 2,4 and 6 cycles of treatment,quality of life scale scores and peripheral blood CD3+,CD4+,CD4+/CD8+levels in low-dose group were higher than those in high-dose group(P＜0.05);however,there was no significant difference in serum HE4,CA125 and CA199 levels between the two groups(P＞0.05).The incidence of adverse drug reactions in low-dose group was lower than that in high-dose group(P＜0.05).After 3 years of follow-up,there was no significant difference in median PFS between the two groups(P＞0.05).Conclusion Low-dose Olaparib combined with Bevacizumab in the treatment of elderly patients with platinum-sensi-tive recurrent ovarian cancer has good clinical efficacy,low incidence of adverse drug reactions and high safety.关键词
卵巢肿瘤/奥拉帕利/贝伐珠单抗/人附睾蛋白4/癌抗原125/生活质量/T淋巴细胞亚群/不良反应Key words
Ovarian neoplasms/Olaparib/Bevacizumab/Human epididymis protein 4/Cancer antigen 125/Quality of life/T-lymphocyte subsets/Adverse reaction分类
医药卫生引用本文复制引用
王胜南,马哲,马雪娇..不同剂量奥拉帕利联合贝伐珠单抗治疗老年复发性铂敏感型卵巢癌的效果分析[J].临床误诊误治,2025,38(4):43-49,7.基金项目
2022年度河北省医学科学研究课题计划(20220439) （20220439）
